Zinc‐Organometallic Framework Vaccine Controlled‐Release Zn 2+ Regulates Tumor Extracellular Matrix Degradation Potentiate Efficacy of Immunotherapy
Advanced Science · 2023-09 · 10 (27)
DOI: 10.1002/advs.202302967 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 13.07.2023. Verfasst von Lin Ding und 10 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, 518055, China. Hauptthemen laut MEDLINE: Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program, Guangdong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Tumor extracellular matrix (ECM) not only forms a physical barrier for T cells infiltration, but also regulates multiple immunosuppressive pathways, which is an important reason for immunotherapy failure. The cyclic guanosine monophosphate‐adenosine monophosphate synthase‐stimulator of interferon genes (cGAS‐STING) pathway plays a key role in activating CD8 + T cells, maintaining CD8 + T cells stemness and enhancing the antitumor effect. Herein, a zinc‐organometallic framework vaccine (ZPM@OVA‐CpG) prepared by self‐assembly, which achieves site‐directed release of Zn 2+ in dendritic cell (DC) lysosomes and tumor microenvironment under acidic conditions, is reported. The vaccine actively targets DC, significantly enhances cGAS‐STING signal, promotes DC maturation and antigen cross‐presentation, and induces strong activation of CD8 + T cells. Meanwhile, the vaccine reaches the tumor site, releasing Zn 2+ , significantly up‐regulates the activity of matrix metalloproteinase‐2, degrades various collagen components of tumor ECM, effectively alleviates immune suppression, and significantly enhances the tumor infiltration and killing of CD8 + T cells. ZPM@OVA‐CpG vaccine not only solves the problem of low antigen delivery efficiency and weak CD8 + T cells activation ability, but also achieves the degradation of tumor ECM via the vaccine for the first time, providing a promising therapeutic platform for the development of efficient novel tumor vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, 518055, China.
- Translational Medicine Collaborative Innovation Center, The First Affiliated Hospital (Shenzhen People's Hospital), Southern University of Science and Technology, Shenzhen, 518020, China.
- Guangdong Engineering Technology Research Center of Stem Cell and Cell Therapy, Shenzhen Key Laboratory of Stem Cell Research and Clinical Transformation, Shenzhen Immune Cell Therapy Public Service Platform, Shenzhen,…
- Clinical Laboratory, Jiaozuo Women's and Child's Hospital, Jiaozuo, 454001, China.
- School of Pharmacy, Guangdong Medical University, Dongguan, 523109, China.
- Key Laboratory of Tropical Translational Medicine of Ministry of Education, School of Pharmacy and The First Affiliated Hospital, Hainan Medical University, Haikou, 570228, China.
ORCID-Profile: Yanli Wang
Förderung
- Shenzhen Science and Technology Program
- Guangdong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Ding, L., Liang, M., Li, Y., Zeng, M., Liu, M., Ma, W., Chen, F., Li, C., Reis, R. L., Li, F. R., & Wang, Y. (2023). Zinc‐Organometallic Framework Vaccine Controlled‐Release Zn 2+ Regulates Tumor Extracellular Matrix Degradation Potentiate Efficacy of Immunotherapy. Advanced Science, 10(27). https://doi.org/10.1002/advs.202302967
Vancouver
Ding L, Liang M, Li Y, Zeng M, Liu M, Ma W, et al. Zinc‐Organometallic Framework Vaccine Controlled‐Release Zn 2+ Regulates Tumor Extracellular Matrix Degradation Potentiate Efficacy of Immunotherapy. Advanced Science. 2023;10(27). doi:10.1002/advs.202302967
BibTeX
@article{Ding2023,
author = {Ding, Lin and Liang, Minli and Li, Yuanyuan and Zeng, Mei and Liu, Meiting and Ma, Wei and Chen, Fuming and Li, Chenchen and Reis, Rui L and Li, Fu-Rong and Wang, Yanli},
title = {Zinc‐Organometallic Framework Vaccine Controlled‐Release Zn 2+ Regulates Tumor Extracellular Matrix Degradation Potentiate Efficacy of Immunotherapy},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {27},
doi = {10.1002/advs.202302967}
}
EUVIMED